Olaparib combo improves PFS in metastatic prostate cancer Olaparib combo improves PFS in metastatic prostate cancer
Frontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
FAPI-PET predicts treatment response in patients with rheumatoid arthritis
In this study, they further analyzed data from 19 patients to determine whether FAPI-PET could help predict treatment responses.
All of the patients had high or moderate disease activity and underwent PET/CT exams at baseline, as well as standard F-18 FDG PET/CT scans for comparison. Subsequent treatments included conventional DMARDs (including methotrexate, leflunomide, cyclophosphamide, and tripterygium wilfordii), and synthetic DMARDs (including etanercept, adalimumab, and Janus Kinase inhibitors). Six patients received additional prednisone, and six patients had nonsteroidal anti-inflammatory drugs.Representative Ga-6...
Source: AuntMinnie.com Headlines - January 9, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Nuclear Radiology Source Type: news
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and…#nih #vincerx #paloalto #vincerxpharma #cdk9 #ahmedhamdy #nonhodgkin #ianflinn #phd #vip236 (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2024 Category: Consumer Health News Source Type: news
The Most Exciting New Advancements in Managing and Treating Lupus
The case study involved just one patient: a 20-year-old woman with severe systemic lupus erythematosus (SLE). But the study’s results were so dramatic that they appeared in 2021 in the New England Journal of Medicine.
The woman received a type of cell therapy called CAR-T, which in the past has been used primarily to treat cancer. CAR-T cell therapy involves altering a patient’s immune cells so that they identify and attack problems or pathogens. In people with cancer, that attack is aimed at the diseased cells. But in the NEJM case study, the therapy was directed at the woman’s own B cells,...
Source: TIME: Health - December 27, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Short Steroid Taper Tested With Tocilizumab for GCA Short Steroid Taper Tested With Tocilizumab for GCA
Results from a pilot study examining a shortened prednisone taper of 8 weeks ' length rather than 26 weeks suggest it may be possible to reduce patients ' duration of exposure to glucocorticoids.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 11, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
What is PM2.5 and the AQI?
Discussion
Air quality standards are made, measured and monitored by the US Environmental Protection Agency (EPA) through the Clean Air Act. All potential pollutants are not necessarily monitored. Some of the most commonly monitored and studied are fine particulate matter, ground-level ozone, carbon monoxide, nitrogen dioxide, and sulfur dioxide.
Common fine particulate matter < 2.5 µm (PM2.5) sources include the natural sources of biomass burning, coal burning, road and soil dust, sea spray aerosols, wildfire particles, and volcanic dust. Human sources of PM2.5 include residential cooking and heating, farming, ...
Source: PediatricEducation.org - October 30, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
FDA Approves New Combo Therapy for Prostate Cancer FDA Approves New Combo Therapy for Prostate Cancer
The combination, along with prednisone, is approved for adult patients with BRCA-positive castration-resistant prostate cancer, as determined by an FDA-approved test.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
COVID-19 Cases Are Rising. Should You Get A Booster Shot?
With summer travel in full swing, and masks a distant memory, it’s not entirely surprising that COVID-19 cases are creeping upward again. Along with the increase, some states in the U.S. are also recording upticks in COVID-19 hospitalizations, especially among older people.
According to the Centers for Disease Control and Prevention (CDC), weekly hospitalizations have been rising slightly since the middle of June, from around 6,300 to more than 8,000 for the week ending July 22. The agency no longer reports on national case numbers since the end of the COVID-19 public health emergency in May, meaning state health ...
Source: TIME: Health - August 2, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
TUESDAY, June 6, 2023 -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2023 Category: General Medicine Source Type: news
FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial
First approval of a PARP inhibitor in combination with a new hormonal agent in mCRPC
RAHWAY,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 1, 2023 Category: Drugs & Pharmacology Source Type: news
Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
